sar425899 sanofi dual agonist glp-1 glucagon Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity Focus on Glucagon-like Peptide-1 Target:
Description
#glp1 #diabetes #medication #T2DM | 28 comments on LinkedIn
Thirteen trials involving 5,807 participants were identified
Ph 2 datathat showed weight loss of between 9.4% and 14.7% after 36 weeks on the drug compared to 2.3% for the placebo group and is currently in Ph 3
95% CI 0.89, 0.96) and all-cause mortality rate (HR 0.70
